BLEPHAROSPASM: A RARE ADVERSE EFFECT CAUSED BY LONG-TERM ADMINISTRATION OF OLANZAPINE

Dr.anil Kumar Khatik, Dr. Pooja Dixit, Dr.sushil Kherada, Dr Suresh Gocher, Dr.dheeraj Goya

Abstract


Olanzapine is an atypical (second generation) antipsychotic primarily used for schizophrenia and bipolar disorder . Its common side effects are weight gain, metabolic disturbances including high cholesterol and diabetes mellitus . Blepharospasm is an abnormal involuntary blinking or contraction of muscles of eyelids (orbicularis oculi, proceres and corrugated superciliaris). Blepharospasm is an uncommon adverse effect of Olanzapine and is thought to occur due to blockage of D2 dopamine receptor in the basal ganglia . We are reporting a case of 48 year old female , a known case of chronic schizophrenia since 12 years  , who developed blepharospasm while taking olanzapine 20mg.

Keywords


Olanzapine, blepharospasm, antipsychotics

Full Text:

PDF

References


Tarun Arora / Vikas Maharshi / Harmeet S. Rehan / Pravesh NagarBlepharospasm: an uncommon adverse effect caused by long-term administration of olanzapinePublished Online: 2016-09-22 | DOI: https://doi.org/10.1515/jbcpp-2016-0037

. Levin, H., Reddy, R. Clozapine in the treatment of neuroleptic-induced blepharospasm: a report of four cases. J Clin Psychiatry, 2000; 61: 140–143

Fukui, H., Murai, T. Marked improvement of Meige’s syndrome with olanzapine in a schizophrenic patient. J Neuropsychiatry Clin Neurosci, 2002; 14: 355–356.

Trugman JM, Leadbetter R, Zalis ME, Burgdorf RO, Wooten GF (1994)

Treatment of severe axial tardive dystonia with clozapine: case report and

hypothesis. Mov Disord 9: 441-446

Vahia VN, Naik PM, Deotale P (2007) Unusual case reports: Tardive

oculogyric crisis (tardive syndromes). Indian J Psychiatry 49: 219-220.

Mullen, A. Risperidone and tardive dyskinesia: a case of blepharospasm. Aust N Z J Psychiatry, 2000; 34: 879–880.

Ananth J, Edelmuth E, Dargan B: Meig syndrome associated with neuroleptic treatment. Am J Psychiatry 1988; 145:513–514Google Scholart it is difficult to treat.

Sachdev, P. Tardive blepharospasm. Mov Disord, 1998; 13: 947–951.

Horie C, Suzuki Y, Kiyosawa M, et al. Decreased dopamine D receptor binding in essential blepharospasm. Acta Neurol Scand, 2009; 119(1): 49– 54

Piyasena INAP; Jayasinghe JAC (March 2014). "Mosapride (5HT4 agonist) in the treatment of blepharospasm". Ceylon Med J. 59 (1): 26–27. doi:10.4038/cmj.v59i1.5527. PMID 24682196.

^ Schellini SA, Matai O, Igami TZ, Padovani CR, Padovani CP (2006). "Blefarospasmo essencial e espasmo hemifacial: características dos pacientes, tratamento com toxina botulínica A e revisão da literatura" [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review]. Arquivos Brasileiros de Oftalmologia (in Portuguese). 69 (1): 23–26. doi:10.1590/S0004-27492006000100005. PMID 16491229.


Refbacks

  • There are currently no refbacks.